Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Heart Care LLC

Neither a doctor nor a teaching hospital

Research payments

$1,639,449

144 payments

Through program year 2025, Advanced Heart Care LLC is reported as receiving $1,639,449 in research payments, across 144 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $427,990 24
2024 Research $366,788 15
2023 Research $145,095 18
2022 Research $190,467 20
2021 Research $242,668 33
2020 Research $129,079 19
2019 Research $137,362 15

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $500,035 36 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $363,306 11 payments
  3. American Regent $301,043 10 payments
  4. AstraZeneca Pharmaceuticals LP $211,445 13 payments
  5. Novartis Pharmaceuticals Corporation $129,126 9 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $40,216 11 payments
  7. Amgen Inc. $21,372 5 payments
  8. Pfizer Inc. $20,880 8 payments
  9. Boehringer Ingelheim International GmbH $15,638 7 payments
  10. Esperion Therapeutics, Inc. $13,689 31 payments
Studies the money was for Research payments · program years 2019–2025
  1. 70033093Afl3002 $338,330 21 payments
  2. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $265,300 9 payments
  3. Heart_FID $155,846 4 payments
  4. A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation $152,805 13 payments
  5. Heart_FID $145,197 6 payments
  6. An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) $128,487 4 payments
  7. Obesity Long term safety in patients with CV risk $98,132 3 payments
  8. Forxiga HF-D1699C00001 HF rEF Outcome study $51,128 4 payments
  9. An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $46,259 3 payments
  10. A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) $40,216 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record